focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
we are living in a media age where misinformation spreads wider and faster....sometimes I feel the controversy is encouraged, to create even more advert 'clickbait' response....watch 'Social Dilema'
It's not worth responding to conspiracy theories as they are generally unprovable and not worth the energy....religions are the biggest conspiracy theories of them all and look how many wars religion has begun over the centuries.....dealing with the different agendas on this forum is a challenge already....the science must alway win...IMO....the United Federation of Planets must prevail......LOL
from the narrative at the lst Investor meeting, acquisitions are more like than T/O certainly over the next 12-18 months....I read about (IMMUNOMODULATORY PROGENITOR [iMP] CELLS) technology a while back and the preliminary phase 2 data does show heart scarring cell rejuvination. Again IPs on potential products like this will make NCYT an even more attractive proposition.
“Heart failure is still a major cause of death affecting millions of patients worldwide. Current therapies do not reduce chronic myocardial (heart) scarring, diminish disease progression or prolong life. Thus, the initial Heartcel trial results are very exciting, showing the first evidence in humans of disease reversal, scar reduction and heart regeneration,” said the firm’s chief medical officer Professor Stephen Westaby
most addicts watch the SP go up and down every 15minutes (me included some days)...then if it's lowish volumes, I don't bother, if the volumes are highish I try and find out why......Rcdm do a little deep research to see where the fundamentals are heading and you'll be satisfied I'm sure.
They'll always be PCR testing from Red zone countries....the zones will change to just to zone colours....and don't forget the UK will be a Red zone country, unless BoJo slips a few quid under the table ;-)
@ValJu,
Maybe Earth can come and work for you....I set my sell price at £18....when that trips, I retire....I'm hoping by the end of Winter 21/22...then going to celebrate with a trip to the Maldives for the whole family.....GLA
This one may have been missed by many, but very important for the future of testing.
NCYT collaborating with Joanne Martin. She is a principal investigator of this care home trial using Novacyt rapid testing and National Specialty Advisor for Pathology for NHS England and Improvement.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3835132
larry,
It could be. All depends where the volume is.....NCYT technicians work alongside public and private sector decentralised labs....Couple weeks ago, I went through the Promate process with Katalyst at a Nuffield hospital...all very interesting. After a positive LFT, then went onto PCR validation. The positive Primer results were extrapolated and logged via the NCYT software. These results were uploaded to NYCT HQ, I'm guessing to Bioinformatics dept.
Could be a mobile site in conjunction with:
https://www.stratford.gov.uk/coronavirus/covid-19-community-testing-information.cfm?frmAlias=/community%2Dtesting/
StSmith,
Speculation = French...the biggie will be the 2nd gen LFT antibody for it's value with vaccine companies and world market vaccine purchasing....IP protection is critical, especially UK/Europe and North America.
For the LFT antigen, it's going to be very hard to compete on price with far east generic imports. That's why PCR will always be a NCYT staple.....
let em grind it down !...I fear not, not one bit..... These guys are heading to midcap status, just based on turnover alone. The SP will follow the fundamentals at some point...it has to... The biggest issue NCYT has, is meeting the high demand that's going to go on for the next 2 seasons with adquate levels of available stock...they are already outsourcing for manufacturing support (do the research).
GMs virtues are not just the SP (which he has very little influence on) especially when volumes are low. IMO, last year he had an opportunity with COVID and took the company to another level with it...with acquisitions along the way, product range expansion and sales to boot in the public and private sector here and overseas....re the LTIP bonus, can't blame him one bit taking it 'opportunity of a lifetime'....why not`...plus he never took all of it......Many on the board just get their research from just reading these threads, very lazy IMO....if you did a little deep research you would realise what's really going on ;-)
I agree with the above...In addition, I've also heard that if you don't vote by proxy/ online at the meeting, brokers may vote on your behalf at their discretion. These votes may also be called uninstructed or discretionary broker votes.
Many moons ago, I used to sell vaccines....IMO, AZN (viral vector type) evokes a broader (for variants) stronger viral response which could last longer, but with more of a stronger short term SFX profile e.g. fever, shivers etc....in the past high dose flu vaccines used to be given to older people as they develop less antibodies.....mRNA type seem to be effective, but a less broad suststained protection way than viral vector vaccines....short term SFX e.g. fevers etc. seem to be lower....for me the Pfizer vaccine is more of a cash cow, as mRNA vaccines will need tweaked more to meet the need for emerging variants....like with flu vaccines, they'll be many vaccines type to meet the agae profiles of the world population.....a priority at this stage should be to vaccinate the far flung countries that are still plagued by rediculous mortality rates.
I wonder if NCYT might buyback shares because it believes the market has discounted its shares too steeply. However, I would rather the excess money be used on sales growth, especially around the world in COVID and other diagnostic areas (cancer/ heart desease etc). This is a crucial time for expansion and use the excess money wisely.
remember it's a 'what if' scenario......because it's a game of driving people crazy, desperate, fomo enough and to manipulate the share for the bigger longer picture.... many talk about failed share experiences, but how many cash rich shares have failed.... we're entering the diagnostics age with more to come, not waiting for a mine to strike gold
what if.... it is a clever strategy to make the many so desperate, as soon as it bounces it to mediocre levels say £7-8 the vast majority hands 60 million shares to the instigator who's ready and waiting... for her or she know that theses shares are worth twice that....I keeping my share on the remaining 10 million and am patient enough to find out
I can understand the frustration...Comms could be better, but if there's nothing to report, there's nothing to report.... NCYTs IMO is doing plenty right..... the volumes are still relatively small and NCYT can't do much about the sentiment of those work a shorter term agenda.... we've all expressed our thoughts regarding comms... each to their own how they decide to vote.... for me and after my own deep research, I see a lot of hard work getting product out and getting new customers on board.... patience is key ;-)